Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/26/22 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 05/26/22 | Initial statement of beneficial ownership of securities |
|
2 | ||
| 05/11/22 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
44 | |
| 05/10/22 | Current report filing |
|
|
7 | |
| 04/12/22 | Definitive proxy statements |
|
34 | ||
| 04/01/22 | Current report filing |
|
|
3 | |
| 04/01/22 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 03/31/22 | Statement of changes in beneficial ownership of securities |
|
1 | ||
| 03/11/22 | Annual report pursuant to Section 13 and 15(d) |
|
|
220 | |
| 03/10/22 | Current report filing |
|
|
8 |